Here are six drugmakers' financial results for the third quarter of fiscal year 2017.
Amgen
Amgen reported total revenue of $5.8 billion for the third quarter of FY 2017, down 1 percent from the same period the year prior. Sales of its cancer drug Blincyto jumped 79 percent from the third quarter of FY 2016, while sales of its arthritis drug Enbrel decreased 6 percent.
Bristol-Myers Squibb Co.
Bristol-Myers' third quarter revenue increased 7 percent to $5.3 billion from the same quarter a year prior. Bristol-Myers attributed the increase to strong sales for the cancer drug Opdivo and the blood thinner Eliquis.
Eli Lilly and Co.
The drugmaker's revenue increased 9 percent in the third quarter of FY 2017, largely driven by volume growth from new drug products. New product revenue contributed to a 14 percent volume growth and accounted for about 22 percent of total revenue in the third quarter.
Merck
Merck reported worldwide sales of $10.3 billion for the third quarter of FY 2017, marking a 2 percent decrease from the same quarter a year prior. The drugmaker attributed an estimated $135 million in lost sales to June's NotPetya cyberattack, which forced Merck to temporarily halt drug production.
Novartis
Novartis' third quarter revenue increased 2 percent from the same quarter a year prior to $12.4 billion. The drugmaker's plaque psoriasis drug Cosentyx hit sales of $556 million for the quarter, marking an 83 percent increase from the third quarter of fiscal year 2016.
Teva
Teva reported $5.6 billion in revenue for the third quarter of FY 2017, marking a 1 percent increase from the same quarter a year prior. Facing declining generic drug prices in the U.S. and poor sales of its multiple sclerosis Copaxone, the drugmaker lowered its annual revenue forecast from $22.8-$23.2 billion to $22.2-$22.3 billion.
More articles on supply chain:
6 must-reads for supply chain leaders this week
3 latest FDA approvals
FDA: EpiPen failures attributed to 7 deaths this year